**Supplementary table.** Hazard ratio of baseline characteristics of patients with or without dupilumab-associated conjunctivitis

<table>
<thead>
<tr>
<th>Variables (class cut-off)</th>
<th>Number of patients with or without conjunctivitis</th>
<th>Hazard Ratio</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageclass</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;33</td>
<td>13</td>
<td>0.99</td>
<td>0.47 - 2.09</td>
</tr>
<tr>
<td>&lt;=33</td>
<td>16</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>20</td>
<td>1.59</td>
<td>0.72 - 3.49</td>
</tr>
<tr>
<td>F</td>
<td>9</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>IgE Total IgE levels, KUA/L§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;3637</td>
<td>9</td>
<td>3.15</td>
<td>1.2 - 8.26</td>
</tr>
<tr>
<td>100-3637</td>
<td>12</td>
<td>0.68</td>
<td>0.28 - 1.66</td>
</tr>
<tr>
<td>&lt;=100</td>
<td>8</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Blood eosinophil count on log scale, cells/L§§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;350</td>
<td>17</td>
<td>3.99</td>
<td>1.71 - 9.29</td>
</tr>
<tr>
<td>&lt;=350</td>
<td>12</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>POEM score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;24</td>
<td>4</td>
<td>0.67</td>
<td>0.19 - 2.37</td>
</tr>
<tr>
<td>&gt;16 - &lt;=24</td>
<td>9</td>
<td>0.58</td>
<td>0.21 - 1.62</td>
</tr>
<tr>
<td>&gt;8 - &lt;=16</td>
<td>10</td>
<td>1.13</td>
<td>0.41 - 3.12</td>
</tr>
<tr>
<td>&lt;=8</td>
<td>6</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Peak score on NRS for sleep</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;8</td>
<td>11</td>
<td>1.14</td>
<td>0.53 - 2.44</td>
</tr>
<tr>
<td>&lt;=8</td>
<td>18</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Peak score on NRS for pruritus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;8</td>
<td>17</td>
<td>1.57</td>
<td>0.75 - 3.29</td>
</tr>
<tr>
<td>&lt;=8</td>
<td>12</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>SCORAD score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;76.6</td>
<td>9</td>
<td>2.29</td>
<td>1.04 - 5.05</td>
</tr>
<tr>
<td>&lt;=76.6</td>
<td>20</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>EASI score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;37.7</td>
<td>5</td>
<td>1.12</td>
<td>0.43 - 2.93</td>
</tr>
<tr>
<td>&lt;=37.7</td>
<td>24</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>DLQI score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;20</td>
<td>4</td>
<td>0.55</td>
<td>0.1 - 3.03</td>
</tr>
<tr>
<td>&gt;10 - &lt;=20</td>
<td>20</td>
<td>0.26</td>
<td>0.26 - 4.78</td>
</tr>
<tr>
<td>&gt;6 - &lt;=10</td>
<td>3</td>
<td>0.22</td>
<td>0.22 - 7.78</td>
</tr>
<tr>
<td>0 - 6</td>
<td>2</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Family history of allergic conjunctivitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>5</td>
<td>2.77</td>
<td>1.05 - 7.29</td>
</tr>
<tr>
<td>N</td>
<td>24</td>
<td>Reference</td>
<td></td>
</tr>
</tbody>
</table>

*§* Significant difference in baseline levels of total IgE

*§§* Log scale conversion for blood eosinophil count

© 2020 Esmon Publicidad

doi: 10.18176/jiaci.0481
<table>
<thead>
<tr>
<th>Condition</th>
<th>Y</th>
<th>N</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of conjunctivitis</td>
<td>27</td>
<td>33</td>
<td>Reference</td>
</tr>
<tr>
<td>History of infective conjunctivitis</td>
<td>4</td>
<td>25</td>
<td>Reference</td>
</tr>
<tr>
<td>Other atopic conditions</td>
<td>16</td>
<td>13</td>
<td>Reference</td>
</tr>
</tbody>
</table>

Abbreviation: Dermatology Life Quality Index (DLQI), EASI=Eczema Area and Severity Index (EASI), Hazard Ratio (HR), Numerical Rating Scale (NRS), Patient-Oriented Eczema Measure (POEM), SCORing Atopic Dermatitis (SCORAD). § Performed in 90 patients. §§ Performed in 89 patients.